Melanoma-associated antigen 3; MAGE-3
CAT No: ta-461
Synonyms/Alias:Melanoma-associated antigen 3 (243-258); MAGE-3 (243-258)
MAGE-3 (243-258) peptide is a synthetic fragment derived from the melanoma-associated antigen 3 (MAGE-3), a member of the MAGE protein family known for its restricted expression in various tumors and its absence in most normal tissues. As a defined epitope corresponding to amino acids 243 through 258 of the MAGE-3 sequence, this peptide is widely recognized for its immunological relevance, particularly in studies investigating tumor antigenicity, antigen processing, and T cell recognition. Its well-characterized sequence and immunogenic properties have made it a valuable tool in the fields of cancer immunology, epitope mapping, and cellular immune response research.
Immunological studies: MAGE-3 (243-258) is extensively utilized in immunological research to study antigen presentation and T cell epitope recognition. Researchers employ this peptide to characterize the specificity and functional properties of cytotoxic T lymphocytes (CTLs) that target tumor-associated antigens. By exposing immune cells to the peptide in vitro, scientists can assess T cell activation, cytokine secretion, and cytolytic activity, providing insights into the mechanisms underlying tumor immune surveillance and the development of antigen-specific immune responses.
Epitope mapping: The defined sequence of MAGE-3 (243-258) serves as a critical tool for epitope mapping experiments. Utilizing this peptide in assays such as ELISPOT, peptide-MHC tetramer staining, or in vitro stimulation of peripheral blood mononuclear cells enables the identification and quantification of antigen-specific T cell populations. These studies are instrumental in delineating the precise regions of MAGE-3 recognized by the immune system, thereby advancing the understanding of T cell epitope hierarchy and immunodominance in cancer antigens.
Peptide-based assay development: The synthetic nature and immunological significance of this peptide make it suitable for the development and optimization of peptide-based assays. It is frequently incorporated into protocols designed to assess antigen processing and presentation by major histocompatibility complex (MHC) molecules, as well as for validating the performance of immunoassays that detect antigen-specific T cell responses. Its use enables the standardization and reproducibility of experimental systems critical for translational immunology research.
Vaccine research: MAGE-3 (243-258) is an important component in the preclinical evaluation of peptide-based cancer vaccines. By serving as a model antigen, it allows for the investigation of immunogenicity, adjuvant efficacy, and delivery strategies in vitro or in animal models. Researchers leverage its properties to optimize peptide vaccine formulations, assess the induction of antigen-specific immune responses, and explore combination strategies with other immunomodulatory agents, thereby contributing to the rational design of next-generation immunotherapeutic approaches.
Antigen processing studies: The peptide is also employed in mechanistic studies aimed at elucidating the pathways of antigen processing and presentation. By introducing MAGE-3 (243-258) into experimental systems, investigators can dissect the roles of proteasomal degradation, peptide transport, and MHC loading in the generation of tumor antigen-derived epitopes. These studies are essential for understanding the molecular determinants of antigen presentation and for identifying factors that influence the immunogenicity of cancer-associated peptides.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More